Active metabolite from Tamiflu® solution is bioequivalent to that from capsule delivery in healthy volunteers: A cross-over, randomised, open-label study

Vaccine

Volumn 24, Issue 44-46, 2006, Pages 6660-6663

  Brewster, M ^a   Smith, J R ^b   Dutkowski, R ^c   Robson, R ^d  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HOFFMANN LA ROCHE INC   (United States)

^d CCST   (New Zealand)

Author keywords

Active pharmaceutical ingredient (API); Influenza; Oseltamivir; Pharmacokinetic

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; DRUG METABOLITE; OSELTAMIVIR;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SOLUTION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; THERAPEUTIC EQUIVALENCY;

EID: 33846302037     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.080     Document Type: Article

References (32)

1. Barker W.H., and Mullooly J. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 112 (1980) 798-811
2. Kilbourne E.D. The influenza virus and influenza (1975), Academic Press, New York
3. Bridges C.B., Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., and Singleton J.A. Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 52 RR-8 (2003) 1-34 [quiz CE1-4]
4. Hayden F.G. Advances in the prophylaxis and treatment of influenza illness. Am J Manage Care 6 5 (2000) S247-S254
5. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42 (1998) 640-646
6. Nicholson K.G., Aoki F.Y., Osterhaus A.D.M.E., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. The Lancet 355 (2000) 1845-1850 May 27
7. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza A randomized controlled trial. J Am Med Assoc 283 8 (2000) 1016-1024
8. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., and Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163 14 (2003) 1667-1672
9. Nordstrom B, Zhu S, Smith J. Reduced risk of mortality following oseltamivir use: a retrospective cohort study. J Antimicrob Chemother submitted for publication.
10. Nordstrom B.L., Sung I., Suter P., and Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 21 5 (2005) 761-768
11. Hayden F.G., Belshe R., Villanueva C., Lanno R., Hughes C., Small I., et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189 3 (2004) 440-449
12. Welliver R., Monto A., Carewicz O., Schatteman E., Hassman M., Hedrick J., et al. Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA 285 (2001) 748-754
13. WHO. Avian influenza: assessing the pandemic threat (2006), WHO
14. Coulombier D., and Ekdahl K. H5N1 influenza and the implications for Europe. BMJ 331 7514 (2005) 413-414
15. WHO. Avian influenza - new areas with infection in birds - update 34, 13 October, 2005.
16. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., and Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4 8 (2004) 499-509
17. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., and Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45 10 (2001) 2723-2732
18. Yen H.L., Monto A.S., Webster R.G., and Govorkova E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic a/vietnam/1203/04 influenza virus in mice. J Infect Dis 192 4 (2005) 665-672
19. Roberts NA, Wiltshire HR, Mendel DB, Webster RG. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase. In: ASM Biodefense Research Meeting; 2003; Baltimore, MD, USA, 2003.
20. Leneva I.A., Roberts N., Govorkova E.A., Goloubeva O.G., and Webster R.G. The neuraminidase inhibitor GS4014 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48 (2000) 101-115
21. WHO. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. WHO Gloval influenza programme (2004).
22. Wiltshire H., Wiltshire B., Citron A., Clarke T., Serpe C., Gray D., et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B 745 (2000) 373-388
23. He G., Massarella J., and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and it active metabolite Ro 64-0802. Clin Pharmacokinet 37 6 (1999) 471-484
24. Massarella J.W., He G.Z., Dorr A., Nieforth K., Ward P., and Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir [Ro 64-0796/GS4104] in healthy adult and elderly volunteers. J Clin Pharmacol 40 (2000) 836-843
25. Aoki F.Y., Macleod M.D., Paggiaro P., Carewicz O., El Sawy A., Wat C., et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrobial Chemother 51 1 (2003) 123-129
26. Hayden F.G. Pandemic influenza: is an antiviral response realistic?. Pediatr Infect Dis J 23 11 Suppl (2004) S262-S269
27. Diggory P., Fernandez C., Humphrey A., Jones V., and Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322 (2001) 1-4
28. Roche FH-L. Tamiflu oseltamivir phosphate: product information; 2004.
29. GlaxoSmithKline. Zanamivir: prescribing information; 2003.
30. de Jong M.D., Bach V.C., Phan T.Q., Vo M.H., Tran T.T., Nguyen B.H., et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352 7 (2005) 686-691
31. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in The Netherlands. Lancet 363 9409 (2004) 587-593
32. Yuen K.Y., and Wong S.S. Human infection by avian influenza A H5N1. Hong Kong Med J 11 3 (2005) 189-199